Table 3. Multivariate analysis to estimate the risk of ATV/r- over DRV/r-containing antiretroviral therapies for nephrolithiasis.

	Model 1 crude (n=1,057)		Model 2 adjusted (n=1,056)		Model 3 adjusted (n=1,021)
	HR	95%CI	HR	95%CI	HR	95%CI
ATV/r use over DRV/r	27.05	3.687-198.5	27.08	3.680-199.3	21.47	2.879-160.2
Age per 1 year			1.009	0.980-1.039	1.006	0.976-1.037
Male sex			1.939	0.441-8.528	1.202	0.262-5.512
Weight per 1 kg increment			0.988	0.956-1.021	0.979	0.947-1.012
Tenofovir use					0.678	0.313-1.470
Baseline serum uric acid per 1mg/dl increment					1.418	1.150-1.750
Past history of renal stone					1.661	0.520-5.307
Past exposure to IDV					0.491	0.100-2.403

HR, Hazard ratio; CI, confidence interval; ATV/r, ritonavir-boosted atazanavir; DRV/r, ritonavir-boosted darunavir; HIV, IDV, indinavir.